CD155 Expression Predicts Poor Prognosis in OTSCC and Correlates With TIGIT Expression and Tumor Budding
Anticancer Research · 2025
DOI: 10.21873/anticanres.17712 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Shoichi Kimura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Fukuoka University Hospital and School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Receptors, Immunologic, Receptors, Virus, Biomarkers, Tumor, Tongue Neoplasms.
Abstract (Originalsprache)
BACKGROUND/AIM: Oral tongue squamous cell carcinoma (OTSCC) is the most common malignancy of the oral cavity, characterized by aggressive clinical behavior and poor prognosis. Despite treatment advancements, patient survival rates remain unsatisfactory. CD155, an immunoglobulin superfamily member, has been implicated in tumor progression and immune evasion, with its interaction with TIGIT serving as a potential therapeutic target. This study explored the association of CD155 and TIGIT expression with tumor budding (TB) and prognosis in OTSCC. PATIENTS AND METHODS: We retrospectively reviewed the clinicopathological data of patients with primary OTSCC who underwent surgical treatment at Fukuoka University Hospital from April 2002 to December 2021. The inclusion criteria were the availability of pre-treatment tissue specimens and adherence to a consistent treatment strategy. Patients with prior chemotherapy or radiation therapy, unavailable specimens, or non-compliance with the treatment protocol were excluded. CD155 and TIGIT expression levels were assessed with immunohistochemistry assays, and TB was graded. RESULTS: Overall, 35 patients with OTSCC (60% male, mean age 67.1 years) were included. The median follow-up period was 35.1 months. High-grade CD155 expression was observed in eight patients (22.9%), while high TIGIT expression was noted in 13 patients (43.3%). High TB was significantly associated with high CD155 and high TIGIT expression. Patients with high CD155 expression had significantly shorter overall survival (median 21 months vs. 36 months for CD155-low), as did patients with high TIGIT expression (median 22 months vs. 37 months for TIGIT-Low) and those with TB-High (median 20 months vs. 38 months for TB-Low). CONCLUSION: CD155 and TIGIT are potential prognostic biomarkers and may serve as therapeutic targets in OTSCC. Our study highlights the importance of evaluating these markers to improve patient stratification and treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Fukuoka University Hospital and School of Medicine, Fukuoka, Japan.
- Department of Pathology, Fukuoka University Hospital and School of Medicine, Fukuoka, Japan.
- Section of Otolaryngology, Department of Medicine, Fukuoka Dental College, Fukuoka, Japan.
- Department of Pathology, Fukuoka University Hospital and School of Medicine, Fukuoka, Japan; mikikoss@fukuoka-u.ac.jp.
- Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
- Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Zitieren
APA
Kimura, S., Aoki, M., Nishi, K., Takeuchi, T., Yamano, T., Sakata, T., Tsunoda, T., & Hamasaki, M. (2025). CD155 Expression Predicts Poor Prognosis in OTSCC and Correlates With TIGIT Expression and Tumor Budding. Anticancer Research. https://doi.org/10.21873/anticanres.17712
Vancouver
Kimura S, Aoki M, Nishi K, Takeuchi T, Yamano T, Sakata T, et al. CD155 Expression Predicts Poor Prognosis in OTSCC and Correlates With TIGIT Expression and Tumor Budding. Anticancer Research. 2025. doi:10.21873/anticanres.17712
BibTeX
@article{Kimura2025,
author = {Kimura, Shoichi and Aoki, Mikiko and Nishi, Kensuke and Takeuchi, Toranoshin and Yamano, Takafumi and Sakata, Toshifumi and Tsunoda, Toshiyuki and Hamasaki, Makoto},
title = {CD155 Expression Predicts Poor Prognosis in OTSCC and Correlates With TIGIT Expression and Tumor Budding},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17712}
}
EUVIMED